Dapagliflozin and saxagliptin and Ponstel

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Coadministration with mefenamic acid and other inhibitors of UGT1A9 may increase the plasma concentrations of dapagliflozin, which is primarily metabolized by glucuronidation to an inactive metabolite. When a single 10 mg dose of dapagliflozin was given with mefenamic acid (500 mg once, followed by 250 mg every 6 hours for 14 doses), dapagliflozin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by an average of 13% and 51%, respectively, compared to dapagliflozin administered alone. No clinically meaningful effect on 24-hour urinary glucose excretion was observed with the pharmacokinetic changes, hence no dosage adjustment is recommended for dapagliflozin.

Dapagliflozin and saxagliptin

Generic Name: dapagliflozin / saxagliptin

Brand name: Qtern

Synonyms: Dapagliflozin and Saxagliptin

What is Dapagliflozin and saxagliptin?

Ponstel

Generic Name: mefenamic acid

Brand name: Ponstel

Synonyms: n.a.

What is Ponstel?